Global 3D Bioprinting Market Size, Share, Growth Analysis, By Technology(Magnetic Levitation, Inkjet-based), By Application(Medical, Dental), By Material(Hydrogels, Living cells), By Component(Bioprinters, Bioinks), By End-use(Pharmaceutical Companies, Research & Academic Institutions) - Industry Forecast 2024-2031

3D Bioprinting Market size was valued at USD 1.08 billion in 2019 and is poised to grow from USD 1.3 billion in 2023 to USD 5.92 billion by 2031, growing at a CAGR of 20.8% in the forecast period (2024-2031).

The market's leading players are focusing on providing advanced and innovative solutions to meet the growing needs of industries. These prominent firms are investing in research and development to create novel services and materials and are highly focused in forming strategic alliances and collaborating to develop next-generation solutions. For instance, in February 2022, Imaginarium collaborated with Ultimaker to launch a desktop and industrial 3D printer range in India. This collaboration will assist Ultimaker in expanding its business in India, where additive manufacturing is expected to reach a tipping point in the coming years. 'EnvisionTEC, Inc.', 'Organovo Holdings, Inc.', ' 3D Systems, Inc. ', ' CELLINK AB ', ' Stratasys Ltd. ', ' Allevi, Inc. ', ' Rokit Healthcare ', ' Poietis SAS ', ' Aspect Biosystems Ltd. ', ' Cyfuse Biomedical K.K. ', ' Biobots, Inc. ', ' Advanced Solutions, Inc. ', ' regenHU Ltd. ', ' Volumetric, Inc. ', ' Materialise NV ', ' BioBots ', ' Microdrop Technologies GmbH ', ' GeSiM mbH ', ' Luxexcel Group BV ', ' 3D Biotek, LLC ', 'In December 2022, The National Eye Institute (NEI), which is part of the National Institutes of Health, printed a mixture of cells that constitute the outer blood-retina barrier—eye tissue that supports the retina's light-sensing photoreceptors. The approach allows researchers to examine degenerative retinal illnesses such as age-related macular degeneration with a theoretically infinite supply of patient-derived tissue (AMD).', 'In September 2022, The Indian Institute of Science (IISc) announced a collaboration with CELLINK, a bioprinting solutions firm based in Sweden, to give two to three bioprinters to the Centre of Excellence (CoE), each of which uses a different printing technology at its own expense. The Indian Institute of Science is set to open its first specialized center for 3D bioprinting technology in approximately two months (IISc). IISc intends to establish a Center of Excellence in 3D bioprinting at its Centre for Biosystems Science and Engineering (BSSE). The CoE strives to develop the discipline by serving as a reference hub for researchers, biopharma companies, hospitals, and other organizations.', 'In June 2022, REGEMAT 3D, announced a collaboration with Humabiologics, a company that provides human-derived biomaterials for regenerative medicine, in response to rising demand and to serve a broader life sciences customer base of industry partners and academic institutions in the European bioprinting and drug testing market.'

Several pharmaceutical companies are rapidly implementing 3D bioprinting products and technology in the process of discovering and developing novel medications. In comparison to the traditional drug testing technique, 3D bioprinting enables the pharmaceutical sector to test drugs more affordably and safely. The 3D bioprinting process allows pharmaceutical companies to test a medicine in a matter of hours, cutting the three to six years it traditionally takes to develop a new drug. Using 3D bioprinted tissues, R&D teams can test new treatments early on as well as during preclinical investigations. Reduced animal testing, increased productivity, and a more rapid medication development process are all advantages of 3D bioprinting. Furthermore, the growing utilization of 3d printing in cosmetic industry is driving the market growth. The European Commission has banned animal testing for cosmetics since March 2013. As a result, some cosmetics and healthcare companies have used 3D bioprinting to develop cutting-edge 3D tissue models and drug screening methodologies.

The rising usage of 3D bioprinting in advanced dermatology is a major trend observed in the market. Burns and scars, particularly on exposed regions of the body, can have a negative impact on an individual's look. The increased consumer awareness of personal appearance is driving an increase in the number of dermal surgeries and treatments throughout the world. According to the National Institute of Aging in the United States, a significant proportion of the population between the ages of 16 and 33 is adopting advanced dermatology. This is generating enough traction for goods manufacturers. Growing self-care awareness is one of the primary factors driving the growth of the 3D bioprinting market in developed regions. Furthermore, 3D bioprinting in healthcare aids in skin tissue bioprinting.

North America region dominated the 3D Bioprinting market in 2021 and is expected to maintain its dominance throughout the forecast period, owing to increased spending on innovative manufacturing technologies by industrialized countries such as Canada and the United States. Moreover, numerous government agencies, such as the National Aeronautics and Space Administration (NASA), have identified significant R&D investments that can significantly contribute to space applications and produce new technologies that fuel commercial growth.

3D Bioprinting Market size was valued at USD 1.08 billion in 2021 and is poised to grow from USD 1.3 billion in 2022 to USD 5.92 billion by 2030, growing at a CAGR of 20.8% in the forecast period (2023-2030).

The market's leading players are focusing on providing advanced and innovative solutions to meet the growing needs of industries. These prominent firms are investing in research and development to create novel services and materials and are highly focused in forming strategic alliances and collaborating to develop next-generation solutions. For instance, in February 2022, Imaginarium collaborated with Ultimaker to launch a desktop and industrial 3D printer range in India. This collaboration will assist Ultimaker in expanding its business in India, where additive manufacturing is expected to reach a tipping point in the coming years. 'EnvisionTEC, Inc.', 'Organovo Holdings, Inc.', ' 3D Systems, Inc. ', ' CELLINK AB ', ' Stratasys Ltd. ', ' Allevi, Inc. ', ' Rokit Healthcare ', ' Poietis SAS ', ' Aspect Biosystems Ltd. ', ' Cyfuse Biomedical K.K. ', ' Biobots, Inc. ', ' Advanced Solutions, Inc. ', ' regenHU Ltd. ', ' Volumetric, Inc. ', ' Materialise NV ', ' BioBots ', ' Microdrop Technologies GmbH ', ' GeSiM mbH ', ' Luxexcel Group BV ', ' 3D Biotek, LLC ', 'In December 2022, The National Eye Institute (NEI), which is part of the National Institutes of Health, printed a mixture of cells that constitute the outer blood-retina barrier—eye tissue that supports the retina's light-sensing photoreceptors. The approach allows researchers to examine degenerative retinal illnesses such as age-related macular degeneration with a theoretically infinite supply of patient-derived tissue (AMD).', 'In September 2022, The Indian Institute of Science (IISc) announced a collaboration with CELLINK, a bioprinting solutions firm based in Sweden, to give two to three bioprinters to the Centre of Excellence (CoE), each of which uses a different printing technology at its own expense. The Indian Institute of Science is set to open its first specialized center for 3D bioprinting technology in approximately two months (IISc). IISc intends to establish a Center of Excellence in 3D bioprinting at its Centre for Biosystems Science and Engineering (BSSE). The CoE strives to develop the discipline by serving as a reference hub for researchers, biopharma companies, hospitals, and other organizations.', 'In June 2022, REGEMAT 3D, announced a collaboration with Humabiologics, a company that provides human-derived biomaterials for regenerative medicine, in response to rising demand and to serve a broader life sciences customer base of industry partners and academic institutions in the European bioprinting and drug testing market.'

Several pharmaceutical companies are rapidly implementing 3D bioprinting products and technology in the process of discovering and developing novel medications. In comparison to the traditional drug testing technique, 3D bioprinting enables the pharmaceutical sector to test drugs more affordably and safely. The 3D bioprinting process allows pharmaceutical companies to test a medicine in a matter of hours, cutting the three to six years it traditionally takes to develop a new drug. Using 3D bioprinted tissues, R&D teams can test new treatments early on as well as during preclinical investigations. Reduced animal testing, increased productivity, and a more rapid medication development process are all advantages of 3D bioprinting. Furthermore, the growing utilization of 3d printing in cosmetic industry is driving the market growth. The European Commission has banned animal testing for cosmetics since March 2013. As a result, some cosmetics and healthcare companies have used 3D bioprinting to develop cutting-edge 3D tissue models and drug screening methodologies.

The rising usage of 3D bioprinting in advanced dermatology is a major trend observed in the market. Burns and scars, particularly on exposed regions of the body, can have a negative impact on an individual's look. The increased consumer awareness of personal appearance is driving an increase in the number of dermal surgeries and treatments throughout the world. According to the National Institute of Aging in the United States, a significant proportion of the population between the ages of 16 and 33 is adopting advanced dermatology. This is generating enough traction for goods manufacturers. Growing self-care awareness is one of the primary factors driving the growth of the 3D bioprinting market in developed regions. Furthermore, 3D bioprinting in healthcare aids in skin tissue bioprinting.

North America region dominated the 3D Bioprinting market in 2021 and is expected to maintain its dominance throughout the forecast period, owing to increased spending on innovative manufacturing technologies by industrialized countries such as Canada and the United States. Moreover, numerous government agencies, such as the National Aeronautics and Space Administration (NASA), have identified significant R&D investments that can significantly contribute to space applications and produce new technologies that fuel commercial growth.